Stocktoria
iSpecimen Inc. ISPC
Nasdaq · XNAS · stock · Services-Commercial Physical & Biological Research · website · IPO 2021-06-17
iSpecimen Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.9M | $9.3M | $9.9M | $10.4M | $11.1M |
| R&D expense | — | $1.5M | $1.6M | $1.5M | $879,243 |
| Operating income | -$9.0M | -$12.7M | -$11.2M | -$10.2M | -$5.9M |
| Interest expense | — | — | $16,001 | $238,963 | $2.1M |
| Income tax | — | — | $0 | $0 | $0 |
| Net income | -$10.5M | -$12.5M | -$11.1M | -$10.2M | -$9.0M |
| EPS (diluted) | $-2.28 | $-17.58 | $-24.55 | $-1.16 | $-2.09 |
| Operating cash flow | -$4.2M | -$8.3M | -$5.8M | -$5.8M | -$10.7M |
| Free cash flow | -$4.2M | -$8.3M | -$5.8M | -$6.0M | -$10.7M |
| Cash & equivalents | $6.9M | $1.9M | $2.3M | $15.3M | $27.7M |
| Inventory | — | $45,110 | — | — | — |
| Total assets | $9.5M | $9.4M | $15.8M | $24.6M | $35.7M |
| Total liabilities | $6.4M | $6.0M | $6.1M | $4.3M | $5.9M |
| Shareholders' equity | $3.1M | $3.3M | $9.7M | $20.3M | $29.8M |
Source: SEC EDGAR filings · CIK 0001558569 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.